Search   
MSDS  : 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6, 10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmet hyl)-
CAS  : 751-97-3
SYNONYMS  : * Bristacin * Pirrolidinometil-tetraciclina * Prm-TC * Pyrrolidino-methyl-tetracycline * N-(Pyrrolidinomethyl)tetracycline * N-(1-Pyrrolidinylmethyl)-tetracycline * Reverin * Rolitetracycline * SQ 15,659 * Superciclin * Synotodecin * Syntetrex * Syntetrin * Tetracycline, pyrrolidinomethyl- * Transcycline * Velacicline * Velacycline
*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER : QI9150000
CHEMICAL NAME : 2-Naphthacenecarboxamide,
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,
10,12,12a-
pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmet
hyl)-
CAS REGISTRY NUMBER : 751-97-3
LAST UPDATED : 199609
DATA ITEMS CITED : 11
MOLECULAR FORMULA : C27-H33-N3-O8
MOLECULAR WEIGHT : 527.63
WISWESSER LINE NOTATION : L E6 C666 BV FV CU GUTTT&J DQ EQ HQ IN1&1 MQ M1 RQ
GVM1- AT5NTJ
COMPOUND DESCRIPTOR : Drug
Reproductive Effector
SYNONYMS/TRADE NAMES :
* Bristacin
* Pirrolidinometil-tetraciclina
* Prm-TC
* Pyrrolidino-methyl-tetracycline
* N-(Pyrrolidinomethyl)tetracycline
* N-(1-Pyrrolidinylmethyl)-tetracycline
* Reverin
* Rolitetracycline
* SQ 15,659
* Superciclin
* Synotodecin
* Syntetrex
* Syntetrin
* Tetracycline, pyrrolidinomethyl-
* Transcycline
* Velacicline
* Velacycline

*** HEALTH HAZARD DATA ***

** ACUTE TOXICITY DATA **

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 1320 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JPPMAB Journal of Pharmacy and Pharmacology. (Pharmaceutical Soc. of Great
Britain, 1 Lambeth High St., London SEI 7JN, UK) V.1- 1949-
Volume(issue)/page/year: 16,33,1964

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 225 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
USXXAM United States Patent Document. (U.S. Patent Office, Box 9,
Washington, DC 20231) Volume(issue)/page/year: #3846486

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 75 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 9,63,1959

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 93 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,914,1982

TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rabbit
DOSE/DURATION : 47 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,914,1982

** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 1400 mg/kg/7D-I
TOXIC EFFECTS :
Related to Chronic Data - death
REFERENCE :
JJANAX Japanese Journal of Antibiotics. (Japan Antibiotics Research Assoc.,
2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan) V.21- 1968-
Volume(issue)/page/year: 25,95,1972

** REPRODUCTIVE DATA **

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE : 91 mg/kg
SEX/DURATION : female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
Reproductive - Specific Developmental Abnormalities - eye/ear
Reproductive - Specific Developmental Abnormalities - craniofacial
(including nose and tongue)
REFERENCE :
AGACBH Agents and Actions, A Swiss Journal of Pharmacology. (Birkhaeuser
Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1969/70-
Volume(issue)/page/year: 4,54,1974

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Rodent - rat
DOSE : 91 mg/kg
SEX/DURATION : female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
Reproductive - Specific Developmental Abnormalities - eye/ear
Reproductive - Specific Developmental Abnormalities - craniofacial
(including nose and tongue)
REFERENCE :
AGACBH Agents and Actions, A Swiss Journal of Pharmacology. (Birkhaeuser
Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1969/70-
Volume(issue)/page/year: 4,54,1974

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE : 450 mg/kg
SEX/DURATION : female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
resorbed implants per total number of implants)
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho
Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970-
Volume(issue)/page/year: 3,75,1972

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE : 300 mg/kg
SEX/DURATION : female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho
Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970-
Volume(issue)/page/year: 3,75,1972

TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE : 900 mg/kg
SEX/DURATION : female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho
Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970-
Volume(issue)/page/year: 3,75,1972

*** END OF RECORD ***
Search More   
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
Myxovalargin A 82658-75-1
Myxovalargin B 85568-63-4
4-Morpholinepropanamine,N-(5-chloro-2-nitrobenzo(b)thien-3-yl)- 149338-22-7
Myxovalargin C 85568-64-5
Myxovalargin D 85568-65-6
Naematolin 11054-16-3
Nagase (bacillus subtilis) 11054-16-3
Najatoxin 11054-16-3
Named reagents and solutions, cpd 39374-34-0
4a-epi-Nanaomycin B 72691-97-5
Nandina domestica Thunb., stem extractSUBSTANCE DEFINITION :Plant containing berberine-type alkaloidsREFERENCE :YKKZAJ Yakugaku Zasshi. Journal of Pharmacy. (Nippon Yakugakkai, 2-12-15Shibuya, Shibuya-ku, Tokyo 150, Japan) No.1- 1881-Volume(issue)/page/year: 82,726,1962 72691-97-5
Naphth(2,3-a)aceanthrylene 84030-79-5
Naphthacene 92-24-0
4-Morpholinepropanamine,N-(3-chlorophenyl)-2,6-dimethyl-N-4-pyridinyl-,mono(2-hydroxybenzoate) 59235-63-1
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 16545-11-2
2-Naphthacenecarboxamide,N-((4-(amidinoamidino)-1-piperazinyl)methyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-diox o-, dihydrochloride 13040-98-7
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo- 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,12a-alpha))-,disulfate (1:2) (salt) 10118-90-8
2-Naphthacenecarboxamide,4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-,monohydrochloride 13614-98-7
2-Naphthacenecarboxamide,7-bromo-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10- 12,12a-pentahydroxy-6-methyl-1,11-dioxo- 4572-56-9
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-1,11-dioxo-N-(hydroxymethyl)-6-methyl-3,6,10,12,12a-pentahydroxy- 1181-54-0
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo- 127-33-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-1,11-dioxo-,monohydrochloride 64-73-3
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo- 57-62-5
4-Morpholinepropanamine,N-(3-chlorophenyl)-beta-methyl-N-4-pyridinyl-, (Z)-2-butenedioate (1:2) 21957-74-4
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-72-2
2-Naphthacenecarboxamide,7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 2013-58-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 79-57-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-,calcium salt (1:1),(4S-(4-alpha,4a-alpha,5-alpha,5a-alpha,6-beta,12a-alpha))- 7179-50-2
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,disodium deriv., dihydrate 6153-65-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-2,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-,monohydrochloride, mixed with potassium nitrite 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, compd.with sodium nitrite (1:3) 2058-46-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a- hexahydroxy-6-methyl-1,11-dioxo-, sodiumsalt 69766-62-7
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12, 12a-hexahydroxy-6-methyl-1,11-dioxo-,sulfate 64038-91-1
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-,bis(2-hydroxybenzoate) 21928-15-4
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-((4-(2-hydroxyethyl)-1-piperazinyl)methyl)-6-methyl-1,11-di oxo- 1110-80-1
2-Naphthacenecarboxamide,4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo- 564-25-0
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo- 60-54-8
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 10592-13-9
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,monohydrochloride 64-75-5
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)- 751-97-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, mononitrate (salt) 20685-78-3
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-,(4S-(4-alpha,4a-alpha,5a-alpha,6-beta,12a-alpha))-,compd. with 4-hydroxy-3-methoxybenzenesulfonate (1:1) 20228-26-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo- 914-00-1
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a- pentahydroxy-6-methylene-1,11-dioxo-,monohydrochloride 3963-95-9
4-Morpholinepropanamine,N-(3-chlorophenyl)-N-4-pyridinyl-beta,2,6-trimethyl-,mono(2-hydroxybenzoate) 23410-76-6
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-9-(morpholinomethyl)-1,11-dioxo- 67238-91-9
2-Naphthacenecarboxamide,N,N'-(ethylenebis((methylimino)methylene))bis(4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-di oxo- 17910-68-8
2-Naphthacenecarboxamide,1,4,4a,5,12,12a-hexahydro-4-(dimethylamino)-1,12-dioxo-6-methyl- 3,10,11,12a-tetrahydroxy-,(4S-(4-alpha,4a-alpha,12a-alpha))- 1665-56-1

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com| Ads link:todaystock.net